Clinical Trial Update: Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older [Phase 1]

View source ↗

Summary

This clinical trial update notes a Phase 1 study assessing the safety and immunogenicity of LYB004, a recombinant zoster vaccine, in adults aged 40 years and ol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• LYB004 (recombinant zoster vaccine)

Snippet

Sponsor: Guangzhou Patronus Biotech Co., Ltd. | Conditions: Herpes Zoster (HZ) | Phase 1 | Status: RECRUITING